myeg, hong seng

A. Sputnik V vaccine has been approved in Russia, Belarus and Argentina and Algeria is set to follow them in January. India also waiting to approve at least three more vaccines - local company Bharat Biotch's COVAXIN, Zydus Cadila's ZyCoV-D and Russia's Sputnik-V.

Sources: 1. https://sg.style.yahoo.com/50-countries-start-covid-19-134206907.html
2. https://www.bbc.com/news/world-europe-53735718
3. https://uk.news.yahoo.com/india-approves-astrazenecas-covid-19-101702292.html


B. "Nothing is stopping us producing the components of the vaccine themselves at facilities in foreign states,"

Source: https://www.theedgemarkets.com/article/putin-says-he-will-receive-covid19-vaccine-when-he-can-urges-mass-vaccination

Russia menggalakkan Sputnik V dikilang di negara lain.
... India will produce about 300 million doses of the Russian Sputnik V vaccine. The production of Sputnik V began in other countries, in particular in India, Korea, Brazil and China. Also, Turkey aims to produce Russia's Sputnik V COVID-19 vaccine domestically but has asked for more information about it

Peluang ini sepatutnya diambil oleh JV VaccineLab-Rafarma untuk dapatkan hak pengeluaran di Indonesia untuk pasaran Indonesia dan ASEAN.

Cuma hakikatnya, persaingan untuk Covid-19 vaksin ini amat sengit......

Happy New Year to DRwarrant and all friends..

Bare AAA+. Stim sokmo. He He

ALSO ANOTHER POSSIBILITY:

In addition to the talks with Russia's Gamaleya Institute, the developer of the Sputnik V Vaccine, Malaysia is also in discussions with Chinese manufacturers Sinovac Biotech Ltd and CanSino Biologics to purchase their vaccines.

The deals with the Chinese and Russian manufacturers will include cooperation with Malaysian companies to carry out fill-and-finish work, Khairy said.

Source: https://www.theedgemarkets.com/article/govt-talks-secure-more-vaccines-russia-pfizer-says-khairy

STILL A POSSIBILITY:

Vaccine Lab JV Rafarma Pharmaceuticals (US) + R. & D. Biocogency Laboratories Inc. (Cyprus) + subsidiary of Rafarma, PJSC Kraspharma (Russia) ———-> Russian or other source country Covid-19 vaccine ———> Indonesia and the ASEAN countries

https://news.yahoo.com/turkey-says-aims-produce-russias-122244828.html

https://www.thestar.com.my/news/world/2020/12/21/belarus-registers-sputnik-v-vaccine-in-first-outside-russia---rdif .

https://sg.news.yahoo.com/argentina-launches-covid-19-vaccines-150726888.html

https://uk.news.yahoo.com/russia-supply-bolivia-2-6-154601972.html

In this QR 1, 2021, Arita's contribution still not included yet, any contribution from Glove and PPE (gowns) contract with MAPU also not included yet and any contribution from construction of Gua Musang Highway also not included yet.

QoQ - 95.53% YoY - -4,077.61%

Boss tak suka glamour. Tak nak kawan dgn reporter. The edge keluar berita kemudian padam. He He

8dragon QR report in red again, no wonder counter can't move..
---------------------------

We can confirm it today or tomorrow...
Just waiting for the QR release...

@jennyhee. Please read carefully:

...nexgram will start rally on jan after all vaccines start hot
***** (I believe it also depend on the incoming result of QR 1, 2021)

...paktua aimed rm 0.50 on april (personal target yer)
***** (I believe it depend on the actual results of the company's ability to secure the vaccine
business)

Repost posting paktua73 yang terawal semasa dia join group NXGRAM. {{{{Dengan andaian keadaan tidak berubah}}}}. He He. . . paktua73, [12.12.20 10:16]
morning all nxgram warriors..
after paktua study the rally pattern for nxgram..
this paktua own personal view..

nexgram will start rally on jan after all vaccines start hot

paktua will start fight here on mid jan


paktua73, [12.12.20 10:18]
paktua aimed rm 0.50 on april (personal target yer)

@OKU_2020. It's okay. I'm kuli only.. He He

Stock: [KANGER]: KANGER INTERNATIONAL BHD

Dec 22, 2020 8:48 AM | Report Abuse

morning all..
hope all happy happy..

thanks dk2866..
Paktua cuti sampai 4 jan..
no trade just chit chat only


tut tut
selamat hari natal..

Tik Tok. Tik Tok. Tik Tok...

The company with NTA 0.1277 and the accumulated loss only 2.686 mil, how can be a GN3 list? Any other risk?

Agree. For me, the share price appreciation also will depend on whether the company can secure any Covid-19 vaccine business or not.

If its only depend on the current new businesses (test kit, tracvirus/safetravelpass,gloves, PPEs (gowns) and the Gua Musang subcontact), I think the price appreciation won't be to high.

As for 2021, the hype for Covid-19 vaccines counters will still kicking. If Nexgram can secure any Covid-19 vaccine business, whether it is for bottling or securing The VaccineLab-Rafarma JV, the price of the Nexgram's shares will be BOOM at an unexpected level He He

The Jan 2021 - April 2021 period will be the interesting period to be monitored concerning the prospect of Nexgram in securing Covid-19 vaccine business.

With the emergence of Rafarma Pharmaceuticals and its Russian subsidiary PJSC Kraspharma as a JV partner with VaccineLabs, Nexgram has a great chance to cater for the Russian Gamaleya Sputnik V vaccine business (in Malaysia or Indonesia).

My great dreams for Nexgram. He He

TracVirus has been facilitated MORE THAN 400,000 Covid-19 tests in Malaysia throughout the year 2020.
Source: Tracvirus.com (APP)

Not to forget, TracVirus also facilitated the Covid-19 test sevices in Indonesia via Nexgram's subsidiary PT NDS Global Teknologi. (No data for the number of tests conducted can be retrieved)
Source: Tracvirus.co.id

And let us not to forget, the probable new FUTURE ENGINE of growth for Nexgram:

....... Covid-19 VACCINE to manufacture and distribute from a JV with Rafarma.

When the Financial Statements of the company is better,
and the development of projects and future prospects of profitability of the company is gained.
the TRUST on the company will grow, THE PRICE MUST BE APPRECIATED.

-------------------------------------------------------------------

The new engines of growth for Nexgram..

1. Covid-19 Test Kits (agreement with MKN/MOH and MTC)
2. Covid-19 Test (via subsidiary in Indonesia)
3. Tracvirus SafeTravelPass (Approved by MKN/ MOH))
4. Medical gloves and PPE (gown) (contract with MAPU in Indonesia)
5. NexgramBottleVaccine (via subsidiary operation)
6. RM118 mil Subcontract of the Gua Musang Highway (subcontract in progress)

From QA at AGM 2020:
1. The company expected to turn profitable earliest in the FY2021.
2. The medical division will potentially contribute to the company growth in near future. A little explanation about the vaccine JV.
3. The Cyberjaya project has been terminated (should be Angkasa Project) caused the big loss in the last QRs (caused by write-off of the land held for property development).
The co also has a plan to use the land for medical center to coop with the medical business expansion.
4. Expected revenues from medical (10 mil) and construction (28 mil) for FY Ended 31 July 2021.
5. The big losses in 4th QR 2020 is from one-off items. Not to be incurred in the next QR reports.
6. The co is positively believes that the medical and construction will be able to contribute for a better net operating cash flow.
7. On the risk to be GN3 listing issuer. The risk is smaller because medical and construction businesses will help the co to increase the shareholders equity and eliminates the possibility of the co to be listed as GN3 listing co.

@char1234 shares too many ....
---------------------------------------
MyEG's NOSH @ 3,772 Million(Price: RM1.87), Nexgram"s NOSH @2,661 Million (Price RM0.05)

Therefore the price failed to shoot not caused by the NOSH.
It caused by other factors especially the tRUST of all investors on Nexgram.
When the TRUST comes, the price of Nexgram's share will go up tremendously.

When the Financial Statements of the company is better,
and the development of projects and future prospects of profitability of the company is gained.
the TRUST on the company will grow, THE PRICE MUST BE APPRECIATED.

Lei Shing Hong Securities Limited, the biggest shareholder (21.6%)

LIST OF TOP 30 SHAREHOLDERS AS AT 30TH SEPTEMBER 2020

1 AFFIN HWANG NOMINEES (ASING) SDN BHD
(Pledged Securities Account for Lei Shing Hong Securities Limited)
1,264,408,250 21.16
2 RHB NOMINEES (TEMPATAN) SDN BHD
(Pledged Securities Account for Hap Seng Insurance Services Sdn Bhd)
273,000,000 4.57
3 CGS - CIMB NOMINEES (TEMPATAN) SDN BHD
(Pledged Securities Account for Lim Nyuk Sang @ Freddy Lim)
105,000,000 1.76
4 TAN SOH GEK 70,069,500 1.17
5 CGS - CIMB NOMINEES (TEMPATAN) SDN BHD
(Pledged Securities Account for Lee Yoke Foong)
69,000,000 1.15
6 KHOO YONG AI 64,050,000 1.07
7 LCP LIMITED 58,074,100 0.97
8 IBRAHIM HUSSAIN 50,000,000 0.84
9 MAYBANK NOMINEES (TEMPATAN) SDN BHD
(Pledged Securities Account for Celeste Assets Sdn Bhd)
35,250,000 0.59
10 PUBLIC NOMINEES (TEMPATAN) SDN BHD
(Pledged Securities Account for Lim Geok Hoon)
35,175,000 0.59
11 KHOO BUCK CHEW 31,185,000 0.52
12 AMSEC NOMINEES (TEMPATAN) SDN BHD
(Pledged Securities Account for Jega Devan A/L M Nadchatiram)
26,520,000 0.44
13 AMSEC NOMINEES (TEMPATAN) SDN BHD
(Pledged Securities Account for Joseph Lee Yok Min @ Ambrose)
24,720,000 0.41
14 PUBLIC NOMINEES (TEMPATAN) SDN BHD
(Pledged Securities Account for Leng Kok Liang)
24,700,000 0.41
15 ALLIANCEGROUP NOMINEES (TEMPATAN) SDN BHD
(Pledged Securities Account for Batu Bara Resources Corporation Sdn Bhd)
23,500,000 0.39
16 JEREMY KHO HUI JAQ 22,650,000 0.38
17 AMSEC NOMINEES (TEMPATAN) SDN BHD
(Pledged Securities Account for Victoria Capital Sdn Bhd)
21,868,500 0.37
18 MAYBANK NOMINEES (TEMPATAN) SDN BHD
(Pledged Securities Account for Ong Yoong Nyock)
20,875,000 0.35
19 LCP LIMITED 19,935,500 0.33
20 TAN BENG SIM 18,756,900 0.31
21 CITIGROUP NOMINEES (ASING) SDN BHD
(Pledged Securities Account for Sunnyvale Holdings Ltd)
17,856,550 0.30
22 CHU SHENG TAUR 16,500,000 0.28
23 CHU SOONG TAU 16,500,000 0.28
24 ONG SOI TAT 16,500,000 0.28
25 MAYBANK NOMINEES (TEMPATAN) SDN BHD
(Pledged Securities Account for Pang Su Siong)
16,000,000 0.27
26 MAYBANK SECURITIES NOMINEES (TEMPATAN) SDN BHD
(Pledged Securities Account for Lu Li)
14,978,250 0.25
27 TA NOMINEES (TEMPATAN) SDN BHD
(Pledged Securities Account for Yee Wei Meng)
14,240,000 0.24
28 QUECK HAN TIONG 14,000,000 0.23
29 KENANGA NOMINEES (TEMPATAN) SDN BHD
(Pledged Securities Account for Chong Kon Tet)
13,421,000 0.22
30 UOB KAY HIAN NOMINEES (ASING) SDN BHD
(Pledged Securities Account for UOB Kay Hian Pte Ltd (A/C Clients))
12,757,391 0.21

@TEEXIANX1840 . Totally agreed.

TEEXIANX1840 there's one reason why nexgram can't fly, because nexgram balls is too big, too heavy to fly...
.......................................................................
Not because of its balls is too big but it need the powerful aphrodisiac.
The Viagra is not so powerful to wake-up its kuku.... He He
Waiting,,,, Keep waiting.....
When the powerful announcement will come?
and when it will wake-up??

Next year? Between Jan 2021 - April 2021 ???

Yes @DRwarrant. Happy holiday.

Happy holiday jennyhee

@jennyhee. Nexgram tried to goreng twp times, but failed...... Waiting for another time to goreng. He He

Malaysia Buys AstraZeneca Covid-19 Vaccine, Negotiating Three Chinese, Russian Vaccines

…. The Malaysian government is finalising agreements to buy Chinese vaccines Sinovac and CanSino, as well as Russia’s Sputnik V shot, that include DOMESTIC FILL-AND-FINISH WORK.

…. The Covid-19 vaccines that have been or will be purchased by the government — Pfizer-BioNTech, the global COVAX Facility, AstraZeneca, Sinovac, CanSino, and Gamaleya — cover 82.8 per cent of Malaysia’s population, or 26.5 million people.

…. Science, Technology and Innovation Minister Khairy Jamaluddin said the Sinovac, CanSino, and Gamaleya vaccine agreements currently being finalised with the Malaysian government would not just include purchasing doses, but also domestic fill-and-finish work and potential tie-ups with the Malaysian research and development (R&D) sector.

Source: https://codeblue.galencentre.org/2020/12/22/malaysia-buys-astrazeneca-covid-19-vaccine-negotiating-three-chinese-russian-vaccines/

Still refering to the theory of the JV is trying to cater the Russian Covid-19 vaccine candidate as one of their targeted product. Based on:

… According to RAFARMA, they are working with one of a Russian national pharmaceutical pioneer established since 1959 with strong research and development team for vaccine research and development in the long-term;
where as its existing network with Russian government and European pharmaceutical companies in terms of sourcing, distribution and conduct clinical trial for established vaccines in the short term.

… VaccinesLab advisors on WHO’s listed Covid-19 vaccine clinical trial results especially in terms of safety and efficacy, as well as comparing the research with Russian vaccines currently under various stages of studies, including phase 1 to 3 clinical trials. The team shall propose to VaccinesLab the relevant vaccines deem suitable for ASEAN market in line with WHO updates and standards.

“The government is also in final negotiations with Sinovac, CanSino and Gamaleya to secure a vaccine supply increase of more than 80% or 26.5 million of the country's total population,” he said in a video on the recent development of Covid-19 vaccine for Malaysians today.

Elaborating, Muhyiddin said the agreements with Sinovac, CanSino and Gamaleya would also provide added value to the local science and technology sectors which would benefit the people and the country’s development. “This includes carrying out vaccine bottling processes in the country, research and development, as well as knowledge sharing and technology transfer,” he said.

Source:https://www.theedgemarkets.com/article/govt-has-signed-agreement-astrazeneca-procure-64-million-doses-covid19-vaccine-says-pm

Note: Gamaleya is refering to Russian Sputnik V covid-19 vaccine developer.

The theory of the JV is trying to cater the Russian Covid-19 vaccine candidate as one of their targeted product.

… According to RAFARMA, they are working with one of a Russian national pharmaceutical pioneer established since 1959 with strong research and development team for vaccine research and development in the long-term;
where as its existing network with Russian government and European pharmaceutical companies in terms of sourcing, distribution and conduct clinical trial for established vaccines in the short term.

… VaccinesLab advisors on WHO’s listed Covid-19 vaccine clinical trial results especially in terms of safety and efficacy, as well as comparing the research with Russian vaccines currently under various stages of studies, including phase 1 to 3 clinical trials. The team shall propose to VaccinesLab the relevant vaccines deem suitable for ASEAN market in line with WHO updates and standards.

Active political dialogue between our two countries have continued to develop. In April, President Vladimir Putin and President Joko Widodo had a telephone conversation to discuss joint measures to combat COVID-19 as a common serious threat.

Later on, Russian company Polysan Ltd delivered to Indonesia medicine for the treatment of patients with severe and moderate forms of coronavirus infection. Now our country is ready to supply the vaccine Sputnik V, which has a 95 percent effectiveness rate.

Note: https://www.thejakartapost.com/academia/2020/12/18/russian-indonesian-ties-turn-70-and-counting.html

Sputnik V can be highly effective against new COVID-19 strain: Vaccine codeveloper

… "According to our information, Sputnik V will be as highly effective against the new strain of the coronavirus found in Europe as against the existing strains. Sputnik V has been showing its efficacy over a period of time despite the previous mutations of S-protein,"

… Dmitriev added that it would jointly work with AstraZeneca, another vaccine manufacturing company, to combat the new mutation strain of the COVID-19.

Source: https://in.news.yahoo.com/sputnik-v-highly-effective-against-111509094.html

https://www.thestar.com.my/business/business-news/2020/12/21/key-alliance-plans-to-buy-30-of-tree-med

Belarus registers Sputnik V vaccine, in first outside Russia - RDIF

Source: https://www.thestar.com.my/news/world/2020/12/21/belarus-registers-sputnik-v-vaccine-in-first-outside-russia---rdif

Key Alliance Bhd to acquire SOCSO Antigen Kit Supplier Tree Med Sdn Bhd
Petaling Jaya, 21 December 2020 - Key Alliance Group Bhd today announced its
intentions to acquire Tree Med Sdn Bhd, a leading local medical devices supplier, in
a deal that will see the Group purchase 30% of Tree Med Sdn Bhd for RM14million.
Tree Med Sdn Bhd, has all the relevant licenses including MDA licenses, National
Pharmaceutical Regulatory Agency (APRA), Ministry of Health and is registered with
MIDA and MITI, and is currently supplying PCR test machines, consumables and
reagents to the Ministry of Health. In addition, Tree Med also currently supplies the
Ministry of Health both antigen and PCR test kits, as well as to bodies like PERKESO,
Makmal Kesihatan Awam and 500 other clinics, private hospitals and private
laboratories throughout Malaysia.
Tree Med also provides products and services concerning blood plasma, dengue test
kits and HIV tests to the same clients across Malaysia.
Key Alliance, in this deal, will automatically be able to supply its CareGene RT PCR
kit via Tree Med's networks to be made available to the Ministry of Health and other
government agencies, as well as other private sector clinics and medical laboratories.
The Group will also be well positioned to explore the supply and distribution of Covid-
19 Vaccines, as Tree Med has an existing pharmaceutical license which allows it to
import and distribute the vaccines. It is already in discussions with various
manufacturers and is in the position to be the local distributor to clinics, private and
public hospitals and government agencies.
The Group is also in discussions with Tree Med to look at local manufacturing of
certain products and services in the medical industry to lower the cost of Covid-19
testing, as well as haematology products and other related consumables in the in-vitro
diagnostic space.
"This acquisition, when completed, will position Key Alliance as a complete player in
the medical supplier market for in-vitro diagnostics, as well as open doors to participate
in future vaccine sales and core lab products. The scope would not be limited to just
Covid-19 vaccines, but include others such as standard annual influenza
vaccinations." Managing Director Roy Ho said.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3115558

The 1st quarter 2021 should be announced at the end of this month. But from the past records, for year end 2018 and year end 2019, the 1st QR of the consecutive years has been announced on the day when they conducted AGM.

This year, Year end 2020, AGM on 23.12, therefore the earliest 1st quarter QR 2021 will be announced on 23.12.2021.

Go.. Gooo. Nexgram...
What these achievements of Nexgram to you? Is it a scam or something???? Only their next QRs will tell us the truth.

1. Covid-19 VACCINE to manufacture and distribute (JV with Rafarma)
2. Covid-19 Test Kits (agreement with MKN/MOH and MTC)
3. Covid-19 Test (via subsidiary in Indonesia)
4. Tracvirus with tracking vaccination is ready (contract with MOH)
5. Tracvirus SafeTravelPass (contract with MOH)
6. Medical gloves and PPE (gown) (contract with MAPU in Indonesia)
7. NexgramBottleVaccine (via subsidiary operation)
8. RM118 mil Subcontract of the Gua Musang Highway (subcontract signed)

1st quarter 2021 QR will be reported soon.. Nexgram Brewwingg..

Good morning paktua73 and other members.

https://codeblue.galencentre.org/2020/12/11/ihme-projects-5000-daily-covid-19-cases-in-malaysia-end-feb/

Sad to hear that and hope the projection wont be a reality. . But it's may spurs the Nexgram' test kit business as per conditions below:

1. Fosun Malaysia COVID-19 PCR Distributor Nexgram received emergency use allocation to Malaysia. Supply to Sabah, Selangor, Negeri Sembilan and Pulau Pinang swab test secured. [8 October 2020] Press Release

2. In addition, RM475mil was allocated for the purchase of Covid-19 test kits, reagents and consumables and this could potentially benefit Hong Seng Consolidated Bhd, ACO Group Bhd and Nexgram Holdings Bhd. (Newspaper Report: https://www.thestar.com.my/business/business-news/2020/11/07/mother-of-all-budgets-to-the-rescue )

@uncleFollower. Agree

Nexgram... Go Go...
Nexgram tetap di hati..
Nexgram bercerai belum
Nexgram... ini "Tag" tetap dibawa. Wohoooo

1. Covid-19 VACCINE to manufacture and distribute (JV with Rafarma)
2. Covid-19 Test Kits (agreement with MKN/MOH and MTC)
3. Covid-19 Test (via subsidiary in Indonesia)
4. Tracvirus with tracking vaccination is ready (contract with MOH)
5. Tracvirus SafeTravelPass (contract with MOH)
6. Medical gloves and PPE (gown) (contract with MAPU in Indonesia)
7. NexgramBottleVaccine (via subsidiary operation)
8. 118 mil Subcontract of the Gua Musang Highway (subcontract signed)

Tak tahan dah. Kena langgar janji.

Nexgram.... Nex gram+gram.
selamat datang paktua73. Tut Tut

I'm holding tight....

..... It also likes the healthcare players due to their defensive earnings qualities and projected recovery in visitation in 2021.

Source: https://www.theedgemarkets.com/article/cgscimb-sectors-watch-out-come-2021

..... It also likes the healthcare players due to their defensive earnings qualities and projected recovery in visitation in 2021.
Source: https://www.theedgemarkets.com/article/cgscimb-sectors-watch-out-come-2021

https://www.malaysiakini.com/news/555363

Test of confidence: Muhyiddin survives but will Anwar?

Adik Zu, masa tu Anwar mungkin bukan lagi ketua pembangkang. He He